Ultragenyx Pharmaceutical Inc. SEC filings RARE
Ultragenyx Pharmaceutical Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Jul 20, 2015. Its latest annual report, Form ARS, was filed on Mar 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (acquisition or sale of assets, results of operations, exit or restructuring costs). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| DEFA14A | Additional proxy material | Mar 27, 2026 | — |
| DEF 14A | Proxy statement | Mar 27, 2026 | May 14, 2026 |
| DEFA14A | Additional proxy material | Mar 28, 2025 | — |
| DEF 14A | Proxy statement | Mar 28, 2025 | May 15, 2025 |
| DEFA14A | Additional proxy material | Apr 26, 2024 | — |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 18, 2024 |
| DEFA14A | Additional proxy material | Apr 24, 2023 | — |
| DEF 14A | Proxy statement | Apr 24, 2023 | — |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 24, 2022 |
| DEFA14A | Additional proxy material | Apr 29, 2021 | — |
| DEF 14A | Proxy statement | Apr 29, 2021 | Jun 24, 2021 |
| DEFA14A | Additional proxy material | Apr 29, 2020 | — |
| DEF 14A | Proxy statement | Apr 29, 2020 | Jun 26, 2020 |
| DEFA14A | Additional proxy material | Apr 22, 2019 | — |
| DEF 14A | Proxy statement | Apr 22, 2019 | Jun 11, 2019 |
| DEFA14A | Additional proxy material | Apr 27, 2018 | — |
| DEF 14A | Proxy statement | Apr 27, 2018 | Jun 19, 2018 |
| DEFA14A | Additional proxy material | Apr 28, 2017 | — |
| DEF 14A | Proxy statement | Apr 28, 2017 | Jun 22, 2017 |
| DEFA14A | Additional proxy material | Apr 18, 2016 | — |
| DEF 14A | Proxy statement | Apr 18, 2016 | Jun 9, 2016 |
Showing 23 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RARE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Novato, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1515673
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.